• Search
  • Helpdesk
  • Sales contact
Get your demo
☰

fundraising

Expanding investor confidence: The strategic value of Patient Reported Outcomes (PROs) in biotech fundraising

biotechfundraisingPRO
For biotech companies engaged in the clinical development of a therapeutic innovation, securing investor trust is as critical as demonstrating the scientific value of their molecule. One powerful yet underleveraged...
Follow us on social media
Subscribe to our newsletter
You may also like

Expanding investor confidence: The strategic value of Patient Reported Outcomes...

Leveraging the potential of Patient Reported Outcome (PRO) data to...

Gastrointestinal Tract Diseases Research: Moving Towards Patient-Centered Clinical Trials

The critical importance of Patient Reported Outcomes (PROs) for Emerging...

Turning experience into evidence: PROs in IBD clinical research

BYOD on the rise

About the author
Picture of Céline Hollinger

Céline Hollinger

Celine brings almost two decades of communications experience in the life sciences. As a co-founder of a healthcare communication agency for over a decade, she has supported top pharma and innovative healthcare companies. Since April 2019, she has been leading marketing and communication at Kayentis with her innovative strategies.

Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20

Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA